CRISPR Therapeutics AG

69.09-1.57-2.22%Vol 2.21M1Y Perf 33.62%
Nov 29th, 2023 16:00 DELAYED
BID68.94 ASK70.66
Open71.38 Previous Close70.66
Pre-Market70.36 After-Market-
 1.27 1.84%  - -
Target Price
101.42 
Analyst Rating
Moderate Buy 1.95
Potential %
46.79 
Finscreener Ranking
★★★★★     60.43
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★+     58.63
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★+     63.83
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
81.63 
Earnings Rating
Strong Buy
Market Cap5.49B 
Earnings Date
7th Nov 2023
Alpha0.00 Standard Deviation0.18
Beta1.56 

Today's Price Range

68.9373.55

52W Range

37.5576.19

5 Year PE Ratio Range

-13.00185.10

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-1.99%
1 Month
77.47%
3 Months
36.76%
6 Months
6.90%
1 Year
33.62%
3 Years
-45.56%
5 Years
80.25%
10 Years
-

TickerPriceChg.Chg.%
CRSP69.09-1.5700-2.22
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
12.60
12.80
0.11
0.12
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-709.40
-5 378.90
-5 186.50
-10 984.70
34.07
RevenueValueIndustryS&P 500US Markets
430.00K
0.01
241.09
74.87
Earnings HistoryEstimateReportedSurprise %
Q03 2023-1.98-1.4128.79
Q02 2023-2.18-0.9855.05
Q01 2023-1.67-0.6759.88
Q04 2022-2.32-1.4139.22
Q03 2022-2.30-2.242.61
Q02 2022-2.23-2.40-7.62
Q01 2022-1.91-2.32-21.47
Q04 2021-1.74-1.84-5.75
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.4657.80Positive
12/2023 FY-3.3732.19Positive
3/2024 QR-1.8210.34Positive
12/2024 FY-5.5616.01Positive
Next Report Date-
Estimated EPS Next Report-1.98
Estimates Count12
EPS Growth Next 5 Years %-
Volume Overview
Volume2.21M
Shares Outstanding79.43K
Shares Float76.18M
Trades Count32.56K
Dollar Volume156.08M
Avg. Volume2.37M
Avg. Weekly Volume2.10M
Avg. Monthly Volume3.26M
Avg. Quarterly Volume1.74M

CRISPR Therapeutics AG (NASDAQ: CRSP) stock closed at 69.09 per share at the end of the most recent trading day (a -2.22% change compared to the prior day closing price) with a volume of 2.21M shares and market capitalization of 5.49B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 410 people. CRISPR Therapeutics AG CEO is Samarth Kulkarni.

The one-year performance of CRISPR Therapeutics AG stock is 33.62%, while year-to-date (YTD) performance is 69.96%. CRSP stock has a five-year performance of 80.25%. Its 52-week range is between 37.55 and 76.19, which gives CRSP stock a 52-week price range ratio of 81.63%

CRISPR Therapeutics AG currently has a PE ratio of -5.40, a price-to-book (PB) ratio of 1.89, a price-to-sale (PS) ratio of 8 499.47, a price to cashflow ratio of 13.10, a PEG ratio of -, a ROA of -26.31%, a ROC of -27.71% and a ROE of -30.48%. The company’s profit margin is 34.07%, its EBITDA margin is -5 186.50%, and its revenue ttm is $430.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from CRISPR Therapeutics AG, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.98 for the next earnings report. CRISPR Therapeutics AG’s next earnings report date is -.

The consensus rating of Wall Street analysts for CRISPR Therapeutics AG is Moderate Buy (1.95), with a target price of $101.42, which is +46.79% compared to the current price. The earnings rating for CRISPR Therapeutics AG stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CRISPR Therapeutics AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CRISPR Therapeutics AG has a Buy technical analysis rating based on Technical Indicators (ADX : 24.26, ATR14 : 4.24, CCI20 : 87.83, Chaikin Money Flow : 0.15, MACD : 6.81, Money Flow Index : 60.52, ROC : 34.78, RSI : 66.70, STOCH (14,3) : 74.31, STOCH RSI : 0.00, UO : 46.81, Williams %R : -25.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CRISPR Therapeutics AG in the last 12-months were: Brendan Smith (Option Excercise at a value of $0), James R. Kasinger (Option Excercise at a value of $0), Kasinger James (Option Excercise at a value of $0), Phuong Khanh Morrow (Option Excercise at a value of $0), Samarth Kulkarni (Option Excercise at a value of $4 034 803), Samarth Kulkarni (Sold 200 000 shares of value $10 009 203 ), Smith Brendan (Sold 0 shares of value $0 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
14 (56.00 %)
14 (56.00 %)
13 (56.52 %)
Moderate Buy
1 (4.00 %)
1 (4.00 %)
1 (4.35 %)
Hold
8 (32.00 %)
8 (32.00 %)
7 (30.43 %)
Moderate Sell
1 (4.00 %)
1 (4.00 %)
1 (4.35 %)
Strong Sell
1 (4.00 %)
1 (4.00 %)
1 (4.35 %)
Summary RatingModerate Buy
1.95
Moderate Buy
1.95
Moderate Buy
1.94

CRISPR Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

CEO: Samarth Kulkarni

Telephone: +41 415613277

Address: Baarerstrasse 14, Zug 6300, , CH

Number of employees: 410

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

Bearish Bullish

61%39%

 

News

Stocktwits